Navigation Links
MGuard(TM) Coronary Stent System Approved in Israel
Date:12/8/2008

TEL AVIV, Israel, December 8 /PRNewswire/ -- InspireMD, Ltd. announced that the MGuard(TM) coronary stent system has been approved for use in Israel by the Israeli Ministry of Health.

The MGuard(TM) stent system presents a novel combination of a coronary stent merged with an embolic protection device. Lifelong embolic protection is achieved by an expandable, flexible fishnet style, micron level knit sleeve that wraps the stent. In addition, MGuard(TM) blocks embolic showers and plaque detachment from the arterial wall, blocking debris at the source during and post procedure. The net is designed to diffuse stent pressure on the vessel wall, thereby reducing injury and lowering the likelihood of restenosis. Since MGuard(TM) received CE Mark approval in November 2007 the product has been met with much enthusiasm and celebrated by leading interventional cardiologists worldwide. "We are very excited about MGuard(TM) being approved for use in Israel so soon" stated Dr. Asher Holzer, InspireMD's President. "Our leading Israeli Interventional Cardiologists have been eager to have this life saving stent system available at their hospitals and already in the few days since the local approval, lives of Israelis have been saved with MGuard(TM)". MGuard's relatively early regulatory approval in Israel may have been partly due to numerous recommendations by local opinion leaders to the Ministry of Health.

InspireMD will celebrate the launch of MGuard(TM) in Israel at the upcoming ICI '08 Meeting in Tel-Aviv, December 8th-9th where MGuard(TM) will be demonstrated at booth #18. In addition, InspireMD will be hosting an inspiring cocktail reception symposium on December 8th at the ICI Meeting, MGuard(TM): A Unique Solution for Managing Embolic Complications in Acute MI and SVG. Martin Leon MD and Chaim Lotan MD will chair the meeting where additional speakers include key world renowned interventional cardiologists Martin Rothman MD and Dariusz Dudek MD.

In the past year, MGuard(TM) has been successfully implanted in complex lesions in live cases at major interventional cardiology congresses such as JIM '08, PCR '08 and TCT '08. The procedures were performed by top opinion leaders including Prof. Antonio Colombo, Prof. Eberhard Grube and Dr. Dariusz Dudek. Two clinical trials with MGuard(TM) are currently underway. The MAGICAL Trial (MGuard in SVG and Native Coronaries Trial) is being conducted in Brazil and the GUARD Trial (MGuard in Acute Myocardial Infarction Study) in Poland. The main objective of the MAGICAL trial is to investigate the safety and efficacy of the MGuard stent in human subjects who are candidates for a PCI due to a narrowing of a native coronary artery or a bypass graft. Since November 2007, 24 patients out of 60 planned have been enrolled. Preliminary angiographic data has demonstrated high acute gain and minimal residual stenosis within the stented segment. Six-month angiographic follow-up has started and enrollment is ongoing.

The GUARD Study is a prospective, multi center study, designed to confirm the feasibility, efficacy and safety of MGuard(TM) in acute MI patients. The GUARD study has reached 18 patients (out of the 60 planned) with acute STEMI who received the MGuard stent with no additional distal embolization or aspiration device. The primary endpoint is ST resolution and TIMI flow, and follow up is up to six months. The study's primary endpoints are complete resolution of ST-segment elevation and restoration of flow through the occluded artery. Intermediate results will be presented this week at the ICI '08 Meeting in Tel-Aviv. iMOS (international MGuard Observational study) will be launched soon. The iMOS study will enroll 1000 patients in an open registry.

About InspireMD

InspireMD, Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting procedures: restenosis, embolic showers, and late thrombosis.

In addition to providing embolic protection and minimizing arterial injury, this promising technology is aimed at providing an effective and uniform drug delivery mechanism for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures. For further information visit http://www.inspire-md.com

    Contact:
    Jonina Ohayon
    Marketing Director
    Tel +972-52-5791120
    jonina@inspire-md.com


'/>"/>
SOURCE InspireMD, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease
6. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
7. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
11. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... The OSHA Training Center at ... Center headquartered in Northern California, has issued an important reminder to employers to ... Employers with workers exposed to high temperatures should establish a complete heat ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):